FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2608191634> ?p ?o ?g. }

• W2608191634 endingPage "818" @default.
• W2608191634 startingPage "805" @default.
• W2608191634 abstract "Abstract The Rho GTPases Rac (Ras-related C3 botulinum toxin substrate) and Cdc42 (cell division control protein 42 homolog) regulate cell functions governing cancer malignancy, including cell polarity, migration, and cell-cycle progression. Accordingly, our recently developed Rac inhibitor EHop-016 (IC50, 1,100 nmol/L) inhibits cancer cell migration and viability and reduces tumor growth, metastasis, and angiogenesis in vivo. Herein, we describe MBQ-167, which inhibits Rac and Cdc42 with IC50 values of 103 and 78 nmol/L, respectively, in metastatic breast cancer cells. Consequently, MBQ-167 significantly decreases Rac and Cdc42 downstream effector p21-activated kinase (PAK) signaling and the activity of STAT3, without affecting Rho, MAPK, or Akt activities. MBQ-167 also inhibits breast cancer cell migration, viability, and mammosphere formation. Moreover, MBQ-167 affects cancer cells that have undergone epithelial-to-mesenchymal transition by a loss of cell polarity and inhibition of cell surface actin-based extensions to ultimately result in detachment from the substratum. Prolonged incubation (120 hours) in MBQ-167 decreases metastatic cancer cell viability with a GI50 of approximately 130 nmol/L, without affecting noncancer mammary epithelial cells. The loss in cancer cell viability is due to MBQ-167–mediated G2–M cell-cycle arrest and subsequent apoptosis, especially of the detached cells. In vivo, MBQ-167 inhibits mammary tumor growth and metastasis in immunocompromised mice by approximately 90%. In conclusion, MBQ-167 is 10× more potent than other currently available Rac/Cdc42 inhibitors and has the potential to be developed as an anticancer drug, as well as a dual inhibitory probe for the study of Rac and Cdc42. Mol Cancer Ther; 16(5); 805–18. ©2017 AACR." @default.
• W2608191634 created "2017-05-05" @default.
• W2608191634 creator A5010373843 @default.
• W2608191634 creator A5016940566 @default.
• W2608191634 creator A5017567149 @default.
• W2608191634 creator A5020224582 @default.
• W2608191634 creator A5021173615 @default.
• W2608191634 creator A5026855277 @default.
• W2608191634 creator A5049213857 @default.
• W2608191634 creator A5061527241 @default.
• W2608191634 creator A5063700847 @default.
• W2608191634 creator A5066604159 @default.
• W2608191634 creator A5076001742 @default.
• W2608191634 creator A5088307900 @default.
• W2608191634 date "2017-05-01" @default.
• W2608191634 modified "2023-10-16" @default.
• W2608191634 title "Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer" @default.
• W2608191634 cites W1490646520 @default.
• W2608191634 cites W1532439114 @default.
• W2608191634 cites W1634818393 @default.
• W2608191634 cites W1764631457 @default.
• W2608191634 cites W1964579181 @default.
• W2608191634 cites W1974220691 @default.
• W2608191634 cites W1981393628 @default.
• W2608191634 cites W2001350636 @default.
• W2608191634 cites W2003322119 @default.
• W2608191634 cites W2007785530 @default.
• W2608191634 cites W2012843157 @default.
• W2608191634 cites W2013377296 @default.
• W2608191634 cites W2016550161 @default.
• W2608191634 cites W2018650187 @default.
• W2608191634 cites W2023612761 @default.
• W2608191634 cites W2034177419 @default.
• W2608191634 cites W2035000040 @default.
• W2608191634 cites W2042264070 @default.
• W2608191634 cites W2042696326 @default.
• W2608191634 cites W2047743989 @default.
• W2608191634 cites W2056811680 @default.
• W2608191634 cites W2066767494 @default.
• W2608191634 cites W2068047364 @default.
• W2608191634 cites W2070512478 @default.
• W2608191634 cites W2071018921 @default.
• W2608191634 cites W2073757235 @default.
• W2608191634 cites W2074075635 @default.
• W2608191634 cites W2075956249 @default.
• W2608191634 cites W2080264636 @default.
• W2608191634 cites W2080778311 @default.
• W2608191634 cites W2087310747 @default.
• W2608191634 cites W2087973518 @default.
• W2608191634 cites W2093487975 @default.
• W2608191634 cites W2103208539 @default.
• W2608191634 cites W2107625881 @default.
• W2608191634 cites W2121810961 @default.
• W2608191634 cites W2124054733 @default.
• W2608191634 cites W2124465965 @default.
• W2608191634 cites W2131137736 @default.
• W2608191634 cites W2142685635 @default.
• W2608191634 cites W2143819289 @default.
• W2608191634 cites W2153086428 @default.
• W2608191634 cites W2156789187 @default.
• W2608191634 cites W2158731289 @default.
• W2608191634 cites W2175210896 @default.
• W2608191634 cites W2207784886 @default.
• W2608191634 cites W2258531487 @default.
• W2608191634 cites W2415913163 @default.
• W2608191634 cites W2465579685 @default.
• W2608191634 cites W4289877050 @default.
• W2608191634 doi "https://doi.org/10.1158/1535-7163.mct-16-0442" @default.
• W2608191634 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5418092" @default.
• W2608191634 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28450422" @default.
• W2608191634 hasPublicationYear "2017" @default.
• W2608191634 type Work @default.
• W2608191634 sameAs 2608191634 @default.
• W2608191634 citedByCount "64" @default.
• W2608191634 countsByYear W26081916342017 @default.
• W2608191634 countsByYear W26081916342018 @default.
• W2608191634 countsByYear W26081916342019 @default.
• W2608191634 countsByYear W26081916342020 @default.
• W2608191634 countsByYear W26081916342021 @default.
• W2608191634 countsByYear W26081916342022 @default.
• W2608191634 countsByYear W26081916342023 @default.
• W2608191634 crossrefType "journal-article" @default.
• W2608191634 hasAuthorship W2608191634A5010373843 @default.
• W2608191634 hasAuthorship W2608191634A5016940566 @default.
• W2608191634 hasAuthorship W2608191634A5017567149 @default.
• W2608191634 hasAuthorship W2608191634A5020224582 @default.
• W2608191634 hasAuthorship W2608191634A5021173615 @default.
• W2608191634 hasAuthorship W2608191634A5026855277 @default.
• W2608191634 hasAuthorship W2608191634A5049213857 @default.
• W2608191634 hasAuthorship W2608191634A5061527241 @default.
• W2608191634 hasAuthorship W2608191634A5063700847 @default.
• W2608191634 hasAuthorship W2608191634A5066604159 @default.
• W2608191634 hasAuthorship W2608191634A5076001742 @default.
• W2608191634 hasAuthorship W2608191634A5088307900 @default.
• W2608191634 hasBestOaLocation W26081916341 @default.
• W2608191634 hasConcept C121608353 @default.
• W2608191634 hasConcept C126322002 @default.
• W2608191634 hasConcept C137738243 @default.

• next